View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 8, 2021updated 07 Jan 2022 5:33am

Hyundai Bioscience finds combination therapy effective against Covid-19

In a study, oral CP-COV03 plus dexamethasone was found to be 2.1 times effective than dexamethasone alone.

Hyundai Bioscience has reported that a combination of the niclosamide-based oral antiviral drug candidate, CP-COV03, with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19 in a study.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Developed by the company’s stakeholder CNPharm, CP-COV03 is a ‘host-directed’ therapy that targets the host cell against the current vaccines and antiviral treatments that act on the virus.

Niclosamide, an anthelmintic therapy, is the active component of CP-COV03 and is claimed to work against several viral diseases.

A steroid drug, dexamethasone is used to treat people with severe Covid-19.

In an efficacy analysis carried out by the company at Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Covid-19-infected hamsters, oral dose of CP-COV03 plus dexamethasone offered 2.1 times increased efficacy than that observed with dexamethasone alone.

The latest study is the first to validate the combined effect of oral antiviral with dexamethasone as a combination therapy for Covid-19.

If CP-COV03 receives emergency use authorization (EUA) in the clinical stage, the combination treatment could potentially be used in patients with severe disease.

Hyundai Bioscience Research Center director Dr Geun-Woo Jin said: “Dexamethasone, being a steroid drug, has a side effect of weakening immunity and we need to find a combination treatment that will give antiviral efficacy instead of weakened immunity.

“CP-COV03 is the best partner for combination with Dexamethasone.”

On concluding the Phase I clinical trial of CP-COV03 for Covid-19, the company plans to seek Korea Food and Drug Administration approval for initiating a Phase II trial of the drug for flu.

Subsequently, Hyundai Bioscience plans to obtain EUA for the drug within the first half of next year.

In June last year, the UK Government granted authorisation to use dexamethasone to treat Covid-19 on the National Health Service (NHS).

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology